Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Clinical guidelines: Expert recommendations for NSAID use: a user-friendly model?

Abramson SB.

Nat Rev Rheumatol. 2011 Mar;7(3):133-4. doi: 10.1038/nrrheum.2010.230. Epub 2011 Jan 25.

PMID:
21263459
2.

The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.

Burmester G, Lanas A, Biasucci L, Hermann M, Lohmander S, Olivieri I, Scarpignato C, Smolen J, Hawkey C, Bajkowski A, Berenbaum F, Breedveld F, Dieleman P, Dougados M, MacDonald T, Mola EM, Mets T, Van den Noortgate N, Stoevelaar H.

Ann Rheum Dis. 2011 May;70(5):818-22. doi: 10.1136/ard.2010.128660. Epub 2010 Sep 10.

3.

Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.

Scheiman JM.

Gastroenterol Clin North Am. 2009 Jun;38(2):305-14. doi: 10.1016/j.gtc.2009.03.006. Review.

PMID:
19446260
5.

Prevalence of NSAID-induced gastrointestinal morbidity and mortality.

Haslock I.

J Rheumatol Suppl. 1990 Feb;20:2-6. Review.

PMID:
2182852
7.

[Recommendations for treatment with nonsteroidal anti-inflammatory drugs].

Bolten WW.

MMW Fortschr Med. 2005 Aug 4;147(31-32):24-7. Review. German.

PMID:
16128192
8.

An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.

Tannenbaum H, Bombardier C, Davis P, Russell AS; Third Canadian Consensus Conference Group..

J Rheumatol. 2006 Jan;33(1):140-57. Epub 2005 Dec 1. Erratum in: J Rheumatol. 2006 Apr;33(4):829. J Rheumatol. 2006 Feb;33(2):440.

PMID:
16331802
9.

Balancing the gastrointestinal benefits and risks of nonselective NSAIDs.

Peura DA, Goldkind L.

Arthritis Res Ther. 2005;7 Suppl 4:S7-13. Epub 2005 Sep 15. Review.

10.

Non-steroidal anti-inflammatory drugs.

Blower PR.

Br J Rheumatol. 1993 Jun;32 Suppl 4:35-8. Review.

PMID:
8508274
11.

A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity.

Conaghan PG.

Rheumatol Int. 2012 Jun;32(6):1491-502. doi: 10.1007/s00296-011-2263-6. Epub 2011 Dec 23. Review.

12.

The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.

Schjerning Olsen AM, Fosbøl EL, Gislason GH.

Basic Clin Pharmacol Toxicol. 2014 Aug;115(2):179-84. doi: 10.1111/bcpt.12244. Epub 2014 Apr 25. Review.

13.

[Meloxicam--the balance of efficacy and safety].

Morović-Vergles J.

Reumatizam. 2008;55(2):85-6. Croatian.

PMID:
19024285
14.

Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.

Scheiman JM, Hindley CE.

Clin Ther. 2010 Apr;32(4):667-77. doi: 10.1016/j.clinthera.2010.04.009. Review.

PMID:
20435236
15.

[Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].

van den Bemt BJ, Benraad HB, Rasker JJ.

Ned Tijdschr Geneeskd. 2007 May 12;151(19):1062-7. Review. Dutch.

PMID:
17552414
16.

Non-steroidal anti-inflammatory drugs and cardiovascular risk--a rheumatologist's.

Whitelaw D.

S Afr Med J. 2007 Dec;97(12):1230. No abstract available.

17.
18.

Improving the risk-benefit ratio of NSAID therapy in the elderly.

Hodinka L.

Scand J Rheumatol Suppl. 1991;91:3-8. Review.

PMID:
1771394
20.

[Gastrointestinal complications of non-steroid anti-inflammatory drugs (NSAID): problems to be solved. Rheumatologist's expert opinion].

Nasonov EL, Karateev AE.

Eksp Klin Gastroenterol. 2006;(2):6-9. Review. Russian. No abstract available.

PMID:
16866255

Supplemental Content

Support Center